TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01478997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flexsure Capsules
Description: Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Carboxy Methyl Cellulose
Study: NCT03473600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Liquid Nitrogen spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide injection
Description: Intralesional Triamcinolone Acetonide injection
Study: NCT04215484

Intervention type: DIAGNOSTIC_TEST
Intervention: serum BNP assessment
Description: serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group

Intervention type: DIAGNOSTIC_TEST
Intervention: serum BNP assessment
Description: serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group

Intervention type: DIAGNOSTIC_TEST
Intervention: serum BNP assessment
Description: serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group
Study: NCT02420951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
Study: NCT04317391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management program
Description: Mindfulness based stress reduction
Study: NCT04110925

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic Mutations
Description: DNA sequencing for mutations to be obtained by bloodwork within 6 months of diagnosis, or by accessing diagnostic bone marrow aspirate slides.

Intervention type: OTHER
Group type: OTHER
Intervention: Inflammatory and lipid markers
Description: Bloodwork to be done for lipid profile, c-reactive protein (CRP), and multiplex chemokine/cytokine analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Computed Tomography (CT) of the heart
Description: Sunnybrook Patients with no history of cardiovascular disease \[ex: past/present coronary artery disease (CAD), peripheral vascular disease (PVD), angina, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or stents\], not pregnant, and able to undergo CT will receive a CT of the heart to look for and quantify any occult coronary artery disease.
Study: NCT04004156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQdisc® Nucleus Replacement Device.
Description: All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
Study: NCT01531673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661
Study: NCT04130789

Intervention type: OTHER
Intervention: compare data patterns by data-driven algorithms to determine sepsis
Description: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis

Intervention type: OTHER
Intervention: compare data patterns by data-driven algorithms to determine sepsis
Description: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis

Intervention type: OTHER
Intervention: compare data patterns by data-driven algorithms to predict sepsis-related mortality
Description: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality

Intervention type: OTHER
Intervention: compare data patterns by data-driven algorithms to predict sepsis-related mortality
Description: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
Study: NCT03801161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
Description: Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP \>5 mg/L in infants within 24 hours of immunization.
Study: NCT03138070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 400 mg daily by mouth continue for 14 days
Study: NCT01699607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine
Description: All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
Study: NCT01855724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Pazopanib
Study: NCT03942523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Communication to promote hygiene behavior
Description: Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.~This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment
Study: NCT01157390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage \& frequency: Fed as need Duration: at least 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast feeding
Description: Breast feeding
Study: NCT01628081

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alga Dunaliella Bardawil placebo
Description: Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dunaliella Bardawil
Description: Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).
Study: NCT01531673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to VX-661
Study: NCT02862080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Description: Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anode tsDCS
Description: Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anode tsDCS
Description: Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
Study: NCT01839747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-CT
Description: Imaging
Study: NCT01803659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: b-carotene

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: retinyl palmitate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01462630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies
Study: NCT03943628

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Familias Unidas

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Study: NCT00164138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor training group
Description: pelvic floor training, electrotherapy, bladder retraining.
Study: NCT03744897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Description: Subjects will receive hypnotic analgesia during 20 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Description: Subjects will receive hypnotic analgesia during 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: a-tDCS
Description: Subjects will receive transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
Study: NCT01531673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to VX-661
Study: NCT03744897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia + a-tDCS
Description: Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hypnotic analgesia + a-tDCS
Description: Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: s-tDCS
Description: Subjects will receive sham transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 0mA, 20 minutes
Study: NCT02227277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-α2b
Description: Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL \> 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-α2b
Description: Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL \> 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks.
Study: NCT03943498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Given PO daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02925858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution_#1
Description: Normal saline infusion mimicking infusion rate of ketamine for a given weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
Study: NCT00413543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early pulmonary lung rehabilitation
Description: early pulmonary rehabilitation, 10 days after discharge
Study: NCT02849743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Syntocinon)
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Syntocinon)
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
Study: NCT03323112

Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: Vaccine for prevention of influenza. Vaccines change by influenza season.
Study: NCT02635308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilaterally Biased Resistance Training / MOVE
Description: High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
Study: NCT01759706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery protocol
Description: ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard perioperative care
Description: Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PONV prophylaxis with Ondansetron + Dexamethasone
Description: Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative mobilization program
Description: Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with naropin + sufentanil
Description: Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia with naropin + sufentanil
Description: Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-anesthetic medication with diazepam
Description: Premedication before general anesthesia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preadmission counselling
Description: Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative bowel preparation with sodium phosphate
Description: Preoperative bowel preparation with oral assumption of sodium phosphate
Study: NCT03250689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as oval shaped, white film coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
Study: NCT01531673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to ivacaftor
Study: NCT01508624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interaction
Description: Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Touch - stress balls
Description: Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD
Description: participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
Study: NCT02490033

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation Catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation Catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation Catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation Catheter
Study: NCT02311673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT02385240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Topical Gel, 0.33 percent (Perrigo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Topical Gel, 0.33 percent (Reference)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT01006252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasisulam-sodium
Description: Administered intravenously on Day 1 of a 28-day cycle, until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
Study: NCT04263272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Body Circuit Training Program
Description: 16 week seated upper body exercise for persons with Spinal Cord Injuries. Participants will attend 2-3 exercise sessions a week, sessions have a mix of SCI community members and inpatients.
Study: NCT01355861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative work exercise
Description: Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Negative work exercise
Description: Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
Study: NCT01325753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Undergo CT-guided CA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT04633525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimum Cup Orientation
Description: Participants will have X-rays taken before surgery to determine the target optimal zone for orientation of the cup implant, using EBRA software. The surgeon may or may not implant in this target zone, depending on what they believe is in the patient's best interest. X-rays will be taken at 12 months after surgery to determine if they target cup orientation was achieved.
Study: NCT04307940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: 220 mg per tablet, two tablets (440 mg), intake a single dose orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: 5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets, intake a single dose orally.
Study: NCT04078295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389-LF
Description: E7389-LF Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389-LF
Description: E7389-LF Intravenous infusion.